EASD 2026: Semaglutide shows promise in treating obesity-related heart failure

This research demonstrates the efficacy of semaglutide for the treatment of obese patients with HF-pEF and type 2 diabetes. This research demonstrates the efficacy of semaglutide for the treatment of obese patients with HF-pEF and type 2 diabetes. Results presented at the EASD 2026 meeting strengthen the existing body of evidence for semaglutide in treating obesity-related heart failure associated with ejection fraction (HF-pEF). Image credit: Shutterstock/[[StockLab] Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can:…

Source: Clinical Trials Arena